Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (BCAB) is a clinical-stage biopharmaceutical innovator advancing conditionally active biologic therapies for cancer treatment. This news hub provides investors and industry professionals with essential updates on the company’s proprietary CAB technology platform, clinical trial progress, and strategic developments.
Access timely press releases covering key milestones including regulatory filings, partnership announcements, and financial results. Our curated collection features updates on antibody-drug conjugate trials, intellectual property expansions, and operational developments across BioAtla’s global facilities.
This resource serves as your primary source for tracking BCAB’s progress in developing tumor-selective therapies. Bookmark this page for direct access to verified corporate communications and objective reporting on clinical advancements. Check regularly for updates on pipeline candidates and business strategy execution.
BioAtla (BCAB) has announced two poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30, 2025. The presentations will showcase the company's proprietary Conditionally Active Biologic (CAB) technology.
The first poster demonstrates CAB anti-Nectin4-antibody drug conjugate's superior efficacy compared to enfortumab vedotin analogue in multiple cancer models. The second presentation focuses on novel senolytic targets and CAB-based drug conjugates for targeting senescence-associated secretory phenotype cells.
The presentations will be held on April 27 and April 28, 2025, featuring research by authors including Jian Chen, Jing Wang, and others. The CAB technology aims to provide a new generation of biologics with improved safety margins and therapeutic index, specifically targeting acidic senescence in cancer and age-related diseases.
BioAtla (BCAB), a clinical-stage biotech company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced an upcoming poster presentation at the 2025 ASCO Annual Meeting. The event will be held both online and at Chicago's McCormick Place Convention Center from May 30–June 3, 2025.
The presentation will feature Phase 2 trial results of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in treating patients with heavily pretreated squamous cell carcinoma of the head and neck. The poster presentation (Abstract #6048, Poster #456) is scheduled for Monday, June 2, 2025, from 9:00 AM to 12:00 PM CDT during the Head and Neck Cancer session.
BioAtla (BCAB) reported its Q4 and full year 2024 financial results, highlighting progress in its clinical programs. The company's CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 study continues with data readout expected mid-2025.
Key highlights include mecbotamab vedotin showing exceptional overall survival in mKRAS NSCLC patients, with 66% one-year and 58% two-year survival rates. Ozuriftamab vedotin demonstrated 45% ORR in HPV-positive SCCHN patients.
Financial results show Q4 2024 R&D expenses of $11.6M (down from $22.7M in Q4 2023) and G&A expenses of $4.6M (down from $5.9M). Net loss was $14.9M compared to $26.9M in Q4 2023. The company ended 2024 with $49.0M in cash, implementing a 30% workforce reduction to extend runway beyond key clinical readouts in 1H 2026.
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced two upcoming poster presentations at prestigious medical conferences.
The company will present at the European Lung Cancer Congress (ELCC) 2025 in Paris, France (March 26-29, 2025) and the Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025 in Scottsdale, Arizona (March 27-29, 2025). The presentation materials will be made available on BioAtla's website under the 'Publication' section following the conferences.
BioAtla (BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has scheduled its Fourth Quarter and Full-Year 2024 financial results announcement for March 27, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial performance and provide business updates. Interested parties can access the call through domestic (800-245-3047) or international (203-518-9765) dial-in numbers using the Conference ID: BIOATLA.
BioAtla (NASDAQ: BCAB) has announced a registered direct offering of 9,679,158 common stock shares, each accompanied by a warrant to purchase one share at $1.19. The combined offering price is $0.9520 per share and warrant. The warrants will be exercisable after six months and expire in 5.5 years.
The offering is expected to generate approximately $9.2 million in gross proceeds, closing around December 20, 2024. The funds will support research and development initiatives, including key clinical programs: BA3182 Phase 1 dose escalation data (2Q25) and Phase 2 expansion data (1H26), and mecbotamab vedotin Phase 2B data in mKRAS NSCLC (1H26). Tungsten Advisors acted as the sole placement agent.
BioAtla presented data on Mecbotamab Vedotin (Mec-V) at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting. The study focused on patients with advanced non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS).
Results indicated improved median overall survival (OS) for Mec-V treated patients with mKRAS compared to wild-type KRAS (wtKRAS). One-year OS was 58% for mKRAS patients versus 23% for wtKRAS patients. Mec-V showed antitumor activity across 9 different mKRAS variants.
Key data highlights from the Phase 2 trial (NCT04681131) include:
- 78 patients enrolled, received Mec-V monotherapy or Mec-V + nivolumab.
- Patients had a median of 3 prior lines of therapy.
- 24 patients (30.7%) had mKRAS NSCLC.
- Median OS was not reached for mKRAS patients vs. 8.7 months for wtKRAS patients.
- 6 responses among 21 efficacy-evaluable mKRAS patients (ORR=28.6%).
AXL expression was highly associated with mKRAS NSCLC. Treatment was well tolerated with a manageable safety profile. A randomized trial of Mec-V in treatment-refractory mKRAS NSCLC is planned for 2025.
BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company, announced a poster presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting in Washington, DC, from December 13–15, 2024.
The presentation, titled Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC, will be delivered by a team of authors including Julia Rotow, Grace K. Dy, and others.
Details of the presentation include:
- Poster Number: PP01.03
- Session Type: Poster Reception
- Session Date and Time: Saturday, December 14, 2024, from 5:40 P.M. – 6:40 P.M. ET
Materials from the presentation will be available on the “Publication” section of BioAtla’s website after the event.
BioAtla (BCAB) reported Q3 2024 financial results and clinical progress. Key highlights include promising data from ozuriftamab vedotin Phase 2 trial in head and neck cancer showing 9-month median overall survival, and evalstotug demonstrating tumor reduction in melanoma patients. The company received FDA guidance for potential registrational trials in 2025. Q3 net loss was $10.6M, with revenue of $11.0M from a licensing agreement. R&D expenses decreased to $16.4M from $28.4M year-over-year. Cash position of $56.5M is expected to fund operations into early 2026.
BioAtla (BCAB), a clinical-stage biotechnology company developing Conditionally Active Biologic antibody therapeutics for solid tumors, will host a conference call and webcast on November 7, 2024, at 4:30 p.m. ET to discuss its third quarter 2024 financial results and business highlights. The financial results press release will be available before the conference call on the company's website. A replay will be accessible through the Investors section.
